NMS Labs
3701 Welsh Road, PO Box 433A, Willow Grove, PA 19090-0437
Phone: (215) 657-4900 Fax: (215) 657-2972
e-mail: nms@nmslabs.com
Robert A. Middleberg, PhD, DABFT, DABCC-TC, Laboratory Director

CONFIDENTIAL

Demo Report

Report Issued 01/05/2009 07:47
Last Report Issued 08/11/2008 08:52

88888
IS TESTING ACCOUNT
Attn: IS Department
3701 Welsh Road
Willow Grove, PA 19090

Patient Name 4860B-POS
Patient ID 4860B-POS
Chain 1
Age Not Given **Gender** Not Given

Workorder 08002417

Received 08/08/2008 15:49

Sample ID 08002417-001
Matrix Blood
Patient Name 4860B-POS
Patient ID 4860B-POS
Container Type Clear vial

Collect Dt/Tm Not Given
Source Not Given

Approx Vol/Weight Not Given

Receipt Notes None Entered

Analysis and Comments	Result	Units	Reporting Limit	Notes
4860B Ziprasidone, Blood				
Analysis by High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)				
Ziprasidone	5000	ng/mL	2.0	
Synonym(s): Geodon®, Zeldox®				
In clinical trials, the following mean Plasma concentrations (+/- 1 sd) were reported in non-fasting subjects at steady-state: 14.8 +/- 6.7 ng/mL (10 mg/day), 44.6 +/- 48 ng/mL (40 mg/day), 118 +/- 80 ng/mL (80 mg/day), 139 +/- 81 ng/mL (120 mg/day). Steady-state concentrations occurred 1 to 3 days following initialization of dosing.				